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Abstract
We defined the maximum-tolerated dose (MTD) of chemoradiotherapy (cisplatin (CDDP)
with 5-fluorouracil (5-FU) and concurrent chemoradiotherapy) for Chinese patients with esophageal
cancer. Twenty-one previously untreated patients with primary esophageal cancer were entered
into this study. Escalating doses of CDDP with 5-FU were administered in a modified Fibonacci
sequence, with concurrent conventional fractionation radiotherapy (CFR) of 60 Gy or 50 Gy. The
starting doses were CDDP 37.5 mg/m2 on day 1, and 5-FU 500 mg/m2 on days 1-5, respectively.
The regimen was repeated 4 times every 28 days. If no dose-limiting toxicity (DLT) was observed,
the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was
declared to be 1 dose level below the level at which DLT appeared. DLT was grade 3 radiation-
induced esophagitis at a dose level of CDDP 60 mg/m2 with 5-FU 700 mg/m2 and concurrent
60 Gy CFR. MTD was defined as CDDP 52.5 mg/m2 with 5-FU 700 mg/m2 and concurrent 50
Gy CFR. The MTD of CDDP with 5-FU and in concurrent chemoradiotherapy for Chinese pa-
tients with esophageal cancer is CDDP 52.5 mg/m2 on day 1 and 5FU 700 mg/m2 on days 1-5,
repeated 4 times every 28 days, and concurrent 50 Gy CFR. Further evaluation of this regimen in
a prospective phase II trial is ongoing.
KEYWORDS: esophageal neoplasm, concurrent chemoradiotherapy, cisplatin, 5-fluorouracil,
dose escalation
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sophageal cancer is the 8 th most common cancer 
worldwide,  with 462,000 new cases per year,  
and the 6 th most common cause of death from cancer,  
with 386,000 deaths in 2002 [1].  The age-standard-
ized incidence rate in China was the highest in the 
world [1] At present,  esophageal cancer remains an 
aggressive,  malignant neoplasm with dismal prognosis.  
Patients undergoing surgery alone had a median sur-
vival ranging from 13 to 19 months and a 5-year sur-
vival rate of 15ｵ to 24ｵ [2].  The 5-year survival 
rate with conventional doses of radiation alone is 0ｵ 
to 10ｵ [3].
　 Since the results of RTOG85ﾝ01 were reported,  
concurrent chemoradiotherapy was considered to be 
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the standard therapy for local advanced esophageal 
cancer [4,  5].  However,  diﬀ erent schemas have been 
adopted in diﬀ erent countries.  The schema used in 
America is a protocol of 50 Gy/25 fractions,  2.0 Gy/
fraction,  CDDP 75 mg/m2 d1,  and 5-Fu 1,000 mg/m2 
d1-d4.  A modiﬁ ed schema is used in Japan: 60 Gy/30 
fractions,  2 Gy/fraction,  with an interval of 7 days 
after 30 Gy,  CDDP 70 mg/m2 d1,  and 5-Fu 700 mg/
m2 d1-d5.  There are no standard schemas in China,  
and diﬀ erent schemas have led to diﬀ erent survival 
results [6ﾝ9].  The classical schema in RTOG is 
widely used because of its good survival results 
[4,  5].  However,  therapy-induced side eﬀ ects were 
severe at the same time.  Herskovic et al. [4] reported 
that the rates of severe and life-threatening side 
eﬀ ects were 44ｵ and 20ｵ,  respectively,  and 2ｵ of 
deaths were observed to be iatrogenic.  Supportive 
therapy in China is not comparable with that in 
America because of economic issues.  This diﬀ erence,  
together with racial diﬀ erences,  makes it unclear 
whether the schema used in RTOG is suitable for 
Chinese patients.  The purpose of our escalation trial 
is to search for a suitable schema for Chinese patients 
with esophageal cancer.  At present,  the cost of con-
current chemoradiotherapy is less than that of surgery 
in China.  Moreover,  the quality of life of patients who 
received chemoradiotherapy is better than that of the 
patients who underwent an operation.  If we can prove 
the eﬃ  ciency of radiotherapy with concurrent cisplatin 
and 5-ﬂ urouracil chemotherapy,  it would be clinically 
meaningful in China,  where the incidence of esopha-
geal cancer is the highest in the world.  Now we are 
planning a phase II trial based on the results of this 
phase I trial.  Thus,  diﬀ erent strategies for treating 
esophageal cancer have been adopted in China than in 
Western countries due to their diﬀ erent cultures and 
economies [10].
　 In China,  late-course accelerated fractionation 
radiotherapy (LAFR) alone is widely used [11,  12],  
and has results comparable to surgery.  LAFR was 
performed as follows: Patients received conventional 
fractionation radiotherapy,  at 2 Gy/fraction,  to a 
dose of 30 Gy in 15 fractions over 3 weeks,  followed 
by accelerated fractionation radiotherapy,  twice a day,  
at 1.5 Gy/fraction,  with a minimal interval of 6 h 
between fractions,  and the overall treatment time was 
5 weeks.  The total dose was 60 Gy.  Shi et al. [11] 
and Han et al. [12] have reported 33ｵ and 32ｵ 
5-year survival rates with the use of LAFR,  respec-
tively.  With controversial survival results [6ﾝ8,  13],  
the role of concurrent chemoradiotherapy in China has 
not been conﬁ rmed.
　 In this study,  we conducted a Phase I clinical trial 
of chemoradiotherapy consisting of cisplatin (CDDP) 
with 5-ﬂ uorouracil (5-FU) and concurrent conven-
tional fractionation radiotherapy (CFR) in advanced 
esophageal carcinomas.
Materials and Methods
　 Eligibility. The 5-year survival rate for con-
current chemoradiotherapy in RTOG85ﾝ01 was 26ｵ,  
which was comparable with that of the surgery.  The 
eligibility criteria in RTOG85ﾝ01 included clinical 
phase II patients.  Moreover,  the quality of life in 
patients who received chemoradiotherapy was better 
than that of the patients who underwent an operation.  
Upon notiﬁ cation of the above issues,  patients them-
selves decided whether to receive chemoradiotherapy 
or surgery.
　 Patients (aged ≧18 years and ≦70 years) with 
primary esophageal squamous cell carcinoma proven 
by histology and staged by thoracoabdominal helical 
computed tomography (CT) (T2ﾝ4,  N0ﾝ1,  M0ﾝ1) were 
eligible for this study.  Due to the fact that endoscopic 
ultrasound was not available in our center,  we evalu-
ated clinical staging based on CT scans [14].  The T 
stage was deﬁ ned by the maximal transverse diameter 
of the esophageal tumor: T1≦2 cm,  T2＞2 cm and 
≦4 cm,  T3＞4 cm.  Tumors indicating an invasion of 
any adjacent structures were classiﬁ ed as T4.  If the 
minimal transverse diameter of the lymph nodes,  in 
mediastinal and celiac,  was larger than 1 cm,  the lymph 
nodes were classiﬁ ed as N1; otherwise,  they were 
classiﬁ ed as N0.  Patients should not have received any 
prior radiotherapy or chemotherapy.  All patients were 
requested to have a Karnofsky performance status ≧
60.  The required laboratory tests included a neutrophil 
count ≧2.0×109/L,  a platelet count ≧100×109/L,  
a hemoglobin count ≧100 g/L,  and serum creatinine,  
aspartate aminotransferase,  alanine aminotransferase,  
and a total serum bilirubin ≦ the upper limits of normal.  
The exclusion criteria consisted of any of the following:
pregnancy; lactation; tracheoesophageal ﬁ stula; a 
history of other malignancies,  with the exception of 
carcinoma in situ of the cervix,  nonmelanomatous skin 
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cancer,  and cancer from which the patient had not been 
disease-free for 5 years; a general medical condition 
preventing combined modality therapy; and a known 
hypersensitivity to CDDP or 5-FU; as well as any use 
of a concurrent antineoplastic therapy.  The procedures 
were approved by the Ethics Committee of Hebei 
Medical University and were performed in accordance 
with the ethical standards of human experimentation and 
with the Helsinki Declaration of 1975,  as revised in 
2000.  All patients provided written informed consent.
　 Pretreatment evaluation. Pretreatment 
evaluation included medical history,  complete physical 
examination,  barium esophagraphy,  chest and abdom-
inal helical CT scan,  upper gastroesophageal endos-
copy,  electrocardiography,  bronchoscopy and bone 
marrow scan (if clinically indicated),  complete blood 
count,  and biochemical proﬁ le.  These pretreatment 
tests were performed during the 2 weeks before treat-
ment initiation.  Patients received physical examina-
tions,  and blood counts were taken once a week or 
more often if necessary.  A biochemical proﬁ le was 
obtained and electrocardiography performed before 
every chemotherapy cycle.
　 Treatment plan. The trial was designed as an 
open-label,  nonrandomized dose-escalation study.  
Groups of at least 3 patients received sequentially 
increasing doses of CDDP and 5-FU concurrently with 
radiotherapy according to Table 1.
　 Chemotherapy. We conducted 4 chemotherapy 
cycles beginning on the ﬁ rst days of weeks 1,  5,  9,  
and 13.  The ﬁ rst and second cycles were concurrent 
with CFR.  CDDP was administered at an infusion 
rate of 1 mg per min on day 1,  followed by a continu-
ous daily intravenous infusion of 5-FU (at least 8 h) 
from day 1 through day 5.  The chemoradiotherapy 
schema is shown in Table 2.
　 Radiotherapy. Radiotherapy was performed 
with conventional fractionation on the ﬁ rst day of 
week 1.  Multiﬁ eld,  external-beam megavoltage radia-
tion was delivered using 6-MeV linear accelerators.  
Patients were treated with 5 daily fractions of 2.0 Gy 
per week over a 6-week period.  The total radiation 
dose was 60 Gy.  All ﬁ elds were treated each day.  
Treatment was given with a combination of anterior-
posterior,  oblique,  or lateral ﬁ elds,  such that the 
dose-to-target volume did not diﬀ er from the dose 
speciﬁ ed at the isocenter by more than 10ｵ.  The 
administered dose was prescribed to the isodose line 
covering the volume at risk.  Port ﬁ lms were taken of 
2 ﬁ elds per week,  or more often if clinically indicated.  
The superior and inferior borders of the radiation 
ﬁ eld were 4 cm beyond the tumor,  and the anterior,  
posterior,  and lateral borders were 2 cm beyond the 
tumor,  as deﬁ ned by barium esophagography and CT.  
Wan et al. [15] and Minsky et al. [16] have reported 
that higher radiation doses do not result in better sur-
vival.  So after we reached more than two DLTs with 
radiotherapy of 60 Gy,  we continued to treat 6 
patients at a DLT dose level equivalent to the radio-
therapy schema,  except with a total dose of 50 Gy.  
The radiation dose was reduced to 50 Gy in the level 
5 dose for the following reasons.  1) At present,  con-
current chemoradiotherapy is regarded as the stan-
dard regimen in patients with local advanced esopha-
geal cancer.  RTOG85ﾝ01 adopted the radiation dose 
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Table 1　　Dose escalation schema
Dose 
level
Radiotherapy
2 Gy/d
CDDP
mg/m2
5-FU
mg/m2
Patient
number
1 60 Gy 37.5 500 3
2 60 Gy 45 600 3
3 60 Gy 52.5 700 3
4 60 Gy 60 700 6
5 50 Gy 60 700 6
Table 2　　Chemoradiotherapy schema
week 1 2 3 4 5 6 9 13
radiotherapy ｜｜｜｜｜ ｜｜｜｜｜ ｜｜｜｜｜ ｜｜｜｜｜ ｜｜｜｜｜ ｜｜｜｜｜
＊ ｜｜｜｜｜ ｜｜｜｜｜ ｜｜｜｜｜ ｜｜｜｜｜ ｜｜｜｜｜
chemotherapy Χ Χ Χ Χ
＊The last 6 patients received radiation treatments of 50 Gy.
3
Lin et al.: Phase I Trial of Escalating-dose Cisplatin with 5-fluorouracil
Produced by The Berkeley Electronic Press, 2008
of 50 Gy [4,  5].  Moreover,  the subsequent trial 
RTOG94ﾝ05 conﬁ rmed that increasing the radiation 
dose did not result in an improved survival rate [16].  
Thus,  50 Gy was the ﬁ nal radiation dose we planned 
to adopt.  2) At the very beginning of our study,  we 
adopted a relatively low chemotherapy dose― half 
the dose in RTOG85ﾝ01.  However,  the radiation dose 
of deﬁ nitive radiotherapy alone in patients with esoph-
ageal cancer is 60 Gy-70 Gy.  For this reason we could 
not guarantee that the eﬀ ect of radiation at 50 Gy plus 
half of the chemotherapy dose in RTOG85ﾝ01 would 
be at least equal to the eﬀ ect of deﬁ nitive radiother-
apy alone with a dose of 60 Gy-70 Gy.  We adopted the 
radiation dose of 60 Gy at the beginning of our study 
for reasons of medical ethics.  After we reached DLT 
at the 60 Gy level,  we reduced the radiation dose to 
50 Gy in order to reduce the toxicities of concurrent 
chemoradiotherapy.  We ﬁ nally concluded the maxi-
mum-tolerated dose (MTD) at the 50 Gy dose level.  3) 
In our subsequent phase II clinical trial of concurrent 
chemoradiotherapy in patients with esophageal cancer 
we adopted this MTD regimen.  In that trial,  late-
course accelerated hyperfractionation radiation with a 
5-year survival rate of 33ｵ [11] was used in the con-
trol group.  The preliminary results were as follows:
The 1-year local control rate and the 1-year survival 
rate in the concurrent chemoradiotherapy group were 
90.2ｵ and 70.4ｵ,  respectively.  The comparable 
survival results proved the eﬀ ect of the MTD regi-
men.
　 Dose escalation and deﬁ nition of DLT.
Concurrent chemotherapy dose escalation was per-
formed using a modiﬁ ed Fibonacci sequence.  Based on 
the signiﬁ cant toxicities observed in RTOG85ﾝ01 [4],  
we chose relatively low doses as the initial dosage:
CDDP 37.5 mg/m2 on day 1 and 5-FU 500 mg/m2 on 
days 1 to 5.  The regimen was repeated 4 times every 
28 days.  The escalation doses were CDDP7.5 mg/m2 
and 5-FU 100 mg/m2.  Every cohort contained at least 
3 patients.  If no dose-limiting toxicity (DLT) was 
observed after the completion of full-dose radiother-
apy and concurrent two-cycle chemotherapy,  the next 
dose level was applied.  However,  repeated adminis-
tration to the same patient was not allowed.  If 1 of 3 
patients treated within a dose level experienced a 
dose-limiting toxicity,  3 additional patients were 
treated at the same level.  If a second patient experi-
enced the same dose-limiting toxicity,  escalation was 
stopped and the MTD was deﬁ ned as the level below 
the dose.  In the escalation trial of phase I,  one dose 
level below DLT was found to be safe,  and its toxici-
ties were tolerable.  This dose level was deﬁ ned as 
MTD according to the international routine [20ﾝ22].
　 Chemotherapy-induced toxicities were graded 
according to the National Cancer Institute common 
toxicity criteria version 2 [17],  and radiotherapy-
induced toxicities were graded according to the 
Radiation Therapy Oncology Group (RTOG) acute 
radiation morbidity scoring criteria [18].  Dose-
limiting toxicity was deﬁ ned as follows: Grade 3 
febrile neutropenia or any Grade 4 neutropenia,  
Grade 3ﾝ4 thrombocytopenia,  Grade 3ﾝ4 anemia,  and 
Grade 3ﾝ4 nonhematologic toxicity except for Grade 3 
nausea,  vomiting,  and anorexia.
　 Dose attenuation. All patients were required 
to ﬁ nish the full-dose radiotherapy and at least 2 con-
current cycles of chemotherapy or be withdrawn from 
this study.  If Grade 3ﾝ4 thrombocytopenia,  Grade 3ﾝ
4 anemia,  Grade 4 neutropenia,  or Grade 3ﾝ4 nonhe-
matologic toxicity occurred (except for Grade 3 nau-
sea,  vomiting,  and anorexia),  both RT and CDDP 
with 5-FU were withheld until the Grade 3 or 4 tox-
icities were no longer present.  If this did not occur 
within 2 weeks,  the patient was withdrawn from the 
study.  If Grade 3 neutropenia alone or Grade 2 
thrombocytopenia occurred,  chemotherapy was 
stopped and radiotherapy continued.  Chemotherapy 
was resumed at the same dose level when the toxicity 
disappeared.
　 Response. Patients were re-evaluated within 4 
weeks after the completion of radiotherapy with con-
current chemotherapy.  Thoracoabdominal helical CT,  
barium esophagram,  and upper gastroesophageal 
endoscopy with biopsy were performed.  Clinical 
responses were classiﬁ ed using the World Health 
Organization deﬁ nitions of tumor response as follows.  
Complete response (CR) is the disappearance of all 
clinical evidence of active tumor.  Partial response 
(PR) is a 50ｵ or greater decrease in the size of the 
primary lesion.  Stable disease (SD) is a less than 
50ｵ decrease to a 25ｵ increase in tumor mass,  with 
no new lesions.  Progressive disease (PD) is a more 
than 25ｵ increase in tumor mass or an appearance of 
new lesions.
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Results
　 Patient characteristics. Between February 
2005 and May 2006,  22 patients with previously 
untreated,  histologically proven primary esophageal 
squamous cell carcinoma were enrolled in this trial.  
The patients’ characteristics are listed in Table 3.  
One patient who only completed one cycle of chemo-
therapy for personal reasons was withdrawn from the 
trial.  The other 21 patients were assessable for toxic-
ity.  Twelve patients (57ｵ) were men and 9 (43ｵ) 
were women.  The median age was 63 years (46ﾝ70),  
and the median Karnofsky performance status was 80.  
5 patients had clinical Stage IIA of the disease,  while 
2 had Stage IIB,  6 had Stage III,  1 had Stage IVA,  
and 7 had Stage IVB (6 were located at the mid-tho-
racic esophagus with supraclavicular lympha nodes 
metastasis,  and 1 with bone metastasis).
　 Hematologic toxicity.  Table 4 describes the 
hematologic toxicities according to dose-level cohort.  
Although rhG-CSF was administered in 71.4ｵ 
(15/21) of patients,  when the white blood count was 
below 4.0×109 and/or the absolute neutrophil count 
was below 2.0×109,  the white blood count was con-
sidered to be below the lower limit of normal,  the 
rates of leucopenia and granulocytopenia were 71.4ｵ 
and 66.7ｵ,  respectively.  However,  most hemato-
logic toxicities were mild to moderate.  Only 9.5ｵ 
(2/21) of patients experienced Grade 3 toxicity.  
Three DLTs occurred in 1 patient at the dose level 5 
of CDDP 60 mg/m2 with 5-FU 700 mg/m2 after 
42 Gy radiotherapy had been delivered.  The nadir of 
the Grade 4 leucopenia,  granulocytopenia,  and throm-
bocytopenia in that patient were 0.6×109/L,  0×
109/L and 8×109/L,  respectively.  Before the blood 
counts were recovered 24 days later,  thrombocyte 
infusion,  antibiotics,  rhG-CSF,  and interferon-11 
were administered.  Anemia was not common,  and was 
mild when it occurred.  No other hematologic DLTs 
occurred during the course of the study.  We therefore 
did not presume that hematologic toxicities can deﬁ ne 
DLT.
　 Nonhematologic toxicity. Nonhematologic 
toxicities of Grade 1ﾝ3 are listed in Table 5.  In spite 
of the appearance of common toxicities,  the therapy 
was well-tolerated.  Most of the toxicities were mild 
and manageable.  Superﬁ cial phlebitis occurred in all 
cases.  Most of the phlebitis cases did not require 
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Table 3　　Patient characteristics
Characteristic No.  of patients N＝21
Percentage of 
patients (%)
Gender
　Male 12 57
　Female 9 43
Age
　Median 63
　Range 46ﾝ70
Karnofsky performance status
　Median 80
　Range 70ﾝ90
Histology
　Squamous cell carcinoma 21 100
Stage
　IIA 5 24
　IIB 2 9
　III 6 29
　IVA 1 5
　IVB 7 33
Tumor location
　Upper 7 33
　Middle 14 67
　Lower 0 0
Table 4　　Hematologic toxicity
Toxicity grade
Dose level (number) Percentage 
(%)1 2 3 4 5
WBC 71.4
　1 0 0 0 2 0 9.5
　2 1 3 0 4 3 52.4
　3 0 0 1 0 0 4.8
　4 0 0 0 0 1 4.8
ANC 66.7
　1 1 2 0 4 2 42.9
　2 0 1 0 1 1 14.3
　3 0 0 1 0 0 4.8
　4 0 0 0 0 1 4.8
PLT 9.5
　2 0 0 0 1 0 4.8
　4 0 0 0 0 1 4.8
HGB 28.6
　1 1 0 1 0 2 19.0
　2 0 0 1 1 0 9.5
ANC, absolute neutroplil count ; HGB, heamoglobin ; WBC, white 
blood cell.
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medical care other than a hydropathic compress of 
odynolydsis in several patients.  All patients experi-
enced fatigue and anorexia.  Some of them were sup-
ported with temporal ﬂ uid replacement.  Neither feed-
ing tubes nor intravenous hyperalimentation were 
needed.  None of our cases stopped or delayed planned 
therapy because of fatigue and/or anorexia.
　At dose level 4,  one of the initial 3 patients experi-
enced Grade 3 esophagitis.  At that point,  3 more 
patients were enrolled.  Another case of Grade 3 
esophagitis was observed in 1 patient.  Similarly,  2 of 
6 patients at dose level 5 experienced Grade 3 esoph-
agitis.  We deﬁ ned Grade 3 esophagitis occurring in 
dose levels 4 and 5 as DLT.  When the same four 
DLTs were observed in 4 patients,  the doses at the 
completion of radiotherapy were 38 Gy,  36 Gy,  
18 Gy,  and 50 Gy,  respectively.  Dose levels 4 and 5 
corresponded to the occurrence of 68.2ｵ (15/22) of 
Grade 3 and 4 nonhematologic toxicities,  as noted in 
Table 6,  while only 18.2ｵ (4/22) of such toxicities 
occurred at dose level 3.  We deﬁ ned CDDP 
52.5 mg/m2 with 5-FU 700 mg/m2 and CFR 50 Gy as 
MTD for Chinese patients with esophageal cancer.
　 Response. All 21 patients were assessable for 
clinical response.  It should be noted that 19ｵ (4/21) 
of the patients achieved CR,  52ｵ (11/21) achieved 
PR,  and 29ｵ (6/21) achieved SD.  No PD was 
observed.  The total response rate was 71ｵ (15/21).
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Table 5　　Nonhematologic toxicity
Toxicity grade
Dose level (number) Percentage 
(%)1 2 3 4 5
Esophagitis 81.0
　1 1 1 1 3 1 33.3
　2 0 2 2 1 1 28.6
　3 0 0 0 2 2 19.0
Trachitis/bronchitis＊
　1 1 1 1 3 2 38.1
Nausea and vomiting 95.2
　1 2 0 0 1 1 19.0
　2 1 2 2 3 4 57.1
　3 0 1 0 2 1 19.0
Anorexia 100.0
　1 3 0 1 0 1 23.8
　2 0 1 0 3 3 33.3
　3 0 2 2 3 2 42.9
Fatigue 100.0
　1 3 0 1 4 3 52.4
　2 0 3 2 2 3 47.6
Superﬁ cial phlebitis 100.0
　1 3 3 3 3 5 81.0
　2 0 0 0 3 1 19.0
Gastritis 2 0 1 1 0 1 14.3
Dematitis＊＊ 100.0
　1 2 3 3 6 5 90.5
　2 1 0 0 0 1 9.6
Constipation 2 0 2 2 1 2 33.3
Diarrhea 2 0 0 0 1 0 4.8
Albumin 81.0
　1 1 3 2 4 3 61.9
　2 1 0 1 1 1 19.0
ALT 38.1
　1 2 1 0 2 2 33.3
　2 1 4.8
AST 1 1 0 0 1 3 23.8
GGT 2 0 0 0 0 1 4.8
Bilirubin 1 0 1 1 2 0 19.0
＊: radiation-induced trachitis and/or bronchitis
＊＊: radiation-induced dermatitis
ALT,  alanine aminotransferase ; AST,  aspartate aminotransferase ; 
GGT,  glutamyltransferase.
Table 6　　Grade 3/4 toxicity
Toxicity grade
Dose level (number) Percentage 
(%)1 2 3 4 5
Esophagitis
　3 0 0 0 2 2 19.0
Nausea and vomiting
　3 0 1 0 2 1 19.0
Anorexia
　3 0 2 2 3 2 42.9
WBC
　3 0 0 1 0 0 4.8
　4 0 0 0 0 1 4.8
ANC
　3 0 0 1 0 0 4.8
　4 0 0 0 0 1 4.8
PLT
　4 0 0 0 0 1 4.8
Total
　number 0 3 4 7 8
　percentage (%) 0 13.6 18.2 68.2%
compare ＜CDDP60 mg/m
2,  
5-Fu 700 mg/m2
＞CDDP60 mg/m2,  
5-Fu 700 mg/m2
　number 7 15
　percentage (%) 31.8% 68.2%
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Discussion
　 Esophageal cancer is a chemosensitive tumor.  
CDDP combined with 5-FU has been studied widely,  
and this regimen has been advocated as the standard 
treatment for squamous cell cancer [19].  
Chemoradiotherapy can be delivered as a deﬁ nitive 
local therapy without surgery in the treatment of 
esophageal cancer.  In RTOG85ﾝ01,  the survival rates 
for chemoradiation at 5 and 8 years were 32ｵ and 
22ｵ,  respectively [5].  Although a phase I study with 
a novel regimen including paclitaxel [20],  oxaliplatin 
[21],  and irinotican [22] has been performed with 
concurrent radiotherapy,  the survival beneﬁ ts remain 
unclear.  What is more,  because of ﬁ nancial problems,  
such novel drugs are not widely accepted by Chinese 
patients with esophageal cancer who are primarily 
from impoverished areas in China.  We adopted CDDP 
with 5-FU combined with concurrent CFR for an 
escalating trial.
　 The results of this Phase I study have indicated 
that the combination of CDDP with 5-FU and concur-
rent CFR as a deﬁ nitive therapy is easily tolerated 
and may have clinical beneﬁ ts for Chinese patients 
with esophageal cancer.  The toxicities below the DLT 
dose level were generally mild to moderate and could 
be managed with conventional strategies.  The doses at 
the MTD level in our trial seem to be somewhat lower 
than those used in other studies from East Asia.
　 A phase II study from the Japan Clinical Oncology 
Group Trial (JCOG) [23] delivered CDDP 70 mg/m2 
on days 1 and 29,  and 5-FU 700/m2/day on days 1ﾝ4 
and 29ﾝ32,  with concurrent CFR (60 Gy in total,  5 
daily fractions per week) to treat esophageal cancer.  
However,  there was an interval of 7 days after 30 Gy,  
which might have lessened the treatment toxicities.  
Nevertheless,  only 77ｵ (46/60) of the patients com-
pleted the whole schema,  and 3.3ｵ (2/60) of toxici-
ties were observed to be iatrogenic.
　 In another similar study from Japan [24],  higher 
doses of CDDP 80 mg/m2 on day 1 and continuous 
infusion of 5-FU 800 mg/m2/day on days 2ﾝ6 were 
reportedly administered with radiotherapy (66.6 Gy in 
total,  1.8 Gy/day,  5 fractions per week),  every 3 to 
4 weeks,  for 2 cycles.  Only 70ｵ (21/30) of the 
patients completed the planned treatment.  Grade 3 
and 4 toxicities were observed in 23 (77ｵ) patients.  
We do not concur that the doses of these 2 chemo-
therapeutic regimens are suitable for Chinese people.
　 Lee has reported a prospective phase II neoadju-
vant chemoradiotherapy study in Korea [25].  In this 
study,  the treatment consisted of 2 cycles of CDDP 
60 mg/m2 on day 1 and 5-FU 1,000 mg/m2 daily as a 
continuous intravenous infusion for 5 days from day 2 
to day 6,  with concurrent hyperfractionated radio-
therapy for a total dose of 48 Gy in 40 fractions.  Due 
to severe toxicities,  including 1 death,  the dose of 
5-FU during the ﬁ rst cycle of chemotherapy was 
reduced,  and it was omitted during the second cycle in 
the latter course of this study.  These results indi-
cated that the 5-FU dose of this regimen was too 
intensive.
　 Zhao et al. [8] have reported the results of a phase 
III randomized study from one of the largest cancer 
centers in China.  The chemotherapeutic regimen con-
sisted of CDDP 25 mg/m2/day and 5-Fu 600 mg/m2/
day i.v.  from days 1ﾝ3 every 4 weeks,  with the ﬁ rst 
and second cycles given during concomitant radiation 
sessions.  No survival beneﬁ ts were achieved,  partly 
because of severe acute therapy-induced toxicities,  as 
follows.  Grade 3 and 4 toxicities occurred in 46ｵ of 
patients,  and 6ｵ of patients had Grade 5 acute tox-
icities.  Obviously,  toxicities also result in poor com-
pliance: Only 43ｵ of patients completed all 4 cycles 
of chemotherapy.
　 In summary,  the concurrent chemoradiotherapy 
schema of MTD dose level is feasible and safe for 
Chinese people with esophageal cancer.  We recom-
mend the following dosage levels in this schema:
CDDP 52.5 mg/m2 on day 1 and 5-FU 700 mg/m2 on 
days 1ﾝ5,  repeated 4 times every 28 days,  plus CFR 
of 50 Gy.  The eﬀ ectiveness of this schedule in esoph-
ageal cancer is currently being further evaluated in a 
prospective Phase II trial.
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